open for business

Highlights from the heart of an expanding Campus

Roslin Innovation Centre has been ‘open for business’  since August 2017, to provide space for companies undertaking strategic, commercial and collaborative research in animal health and biosciences, agri-tech , aquaculture (A3) and One Health industries. Our innovation ecosystem continues to nurture entrepreneurship, growth and collaboration within the dynamic environment of Easter Bush Campus. 

Occupancy is currently at 80%, with over 30 tenant companies accommodated across our office and lab space, ranging from established local and international organisations, start-ups and spin-outs, to community interest companies. 

highlights - year 9

OCTOBER 2025

Tiffany Wood, Co-founder and CEO of Dyneval Ltd

from farm to pharma

Two new products are in the pipeline for Dyneval Ltd, to maximise the opportunity for customers across the life sciences sector to utilise Dyneval's platform measurement technology to make data-driven decisions to raise profits and reduce their carbon footprint.

Dynescan4P: All the benefits of Dynescan technology with four semen samples measured in parallel allowing users to understand semen performance over time, with results correlated with reproductive performance.

Lumero: A new brand for the pharmaceutical sector. The Lumero particle size analyser will provide true particle size distributions at almost any concentration helping to identify hidden issues to accelerate R&D and derisk clinical trials.

Watch announcement video by Dr Tiffany Wood, Co-founder and CEO of Dyneval Ltd.

Members of the Regional Edinburgh Council on a visit to Roslin Innovation Centre with RIC Director

Investment fuels innovation

We recently hosted a visit by the Regional Enterprise Council (REC), the governing bodies of the Edinburgh and South East Scotland (ESES) City Region, the Joint Committee, on the delivery of projects across the city region.

This was an opportunity to showcase the impressive economic activity taking place on Campus, and to demonstrate the impact that has been achieved as a result of investment.

The Group met with Roslin Institute researchers and several tenant companies at Roslin Innovation Centre including Prozymi Biolabs, Axol Bioscience, Excellio Biolabs, Cytochroma, Carcinotech, Askbio,  Roslin Technologies, Oxitec and Beta Bugs. This was followed by several presentations and Q&A sessions.

septemBER 2025

Cytochroma and Kate Cameron, CEO, featured on Nasdaq screen at Times Square

what an ad-venture...

A very special moment for Dr Kate Cameron, CEO of Cytochroma, with a display on Nasdaq MarketSite in Times Square! Cytochroma has been selected as one of only 33 innovators to the Morgan Stanley Inclusive & Sustainable Ventures (MSISV) 2025 Cohort together with members from the Americas, Europe, the Middle East and Africa.

MSISV helps startups and nonprofits grow through access to resources, investment and mentorship to foster a more equitable and sustainable investment landscape. Following the five-month accelerator program, startups in the Lab will present at a global showcase and demo day in February 2026.
 
Cytochroma provides optimised cell models from genetically diverse backgrounds to transform drug discovery, testing and validation—cutting preclinical timelines, saving costs and replacing animal testing.

Roslin Technologies pluripotent stem cells

Stem cell innovation

Roslin Technologies, an anchor tenant at Roslin Innovation Centre, has announced that the Japanese patent office has granted the company's product and method claims for the development of porcine induced pluripotent stem cells (iPSCs).

This breakthrough:
  • Uses a feeder-free, serum-free, non-integrative approach
  • Produces genetically stable porcine iPSCs that can form all tissue types, including muscle and fat
  • Unlocks opportunities in cultivated meat, therapeutic research, disease modelling, drug screening, and genetic engineering
This milestone expands the global IP footprint of Roslin Technologies, and reinforces their leadership in cross-species pluripotent stem cell innovation.

Follow us on LinkedIn for latest updates

Year Eight Highlights

Year Seven Highlights